Investigating the role of tumour-to-skin proximity in predicting nodal metastasis in breast cancer.

Autor: Sivakanthan, Thiviya, Tanner, J., Mahata, B., Agrawal, A.
Zdroj: Breast Cancer Research & Treatment; May2024, Vol. 205 Issue 1, p109-116, 8p
Abstrakt: Background: Understanding the factors influencing nodal status in breast cancer is vital for axillary staging, therapy, and patient survival. The nodal stage remains a crucial factor in prognostication indices. This study investigates the relationship between tumour-to-skin distance (in T1–T3 tumours where the skin is not clinically involved) and the risk of nodal metastasis. Methods: We retrospectively reviewed data from 100 patients who underwent neoadjuvant chemotherapy (NACT). Besides patient demographics and tumour variables, a radiologist retrospectively reviewed pre-operative MRI to measure tumour-to-skin distance. R core packages were used for univariate (χ2 and T-Wilcoxon tests) and bivariate logistic regression statistical analysis. Results: Of 95 analysable datasets, patients' median age was 51 years (IQR: 42–61), 97% were symptomatic (rest screen detected), and the median tumour size was 43 mm (IQR, 26–52). On multivariate analysis, increasing invasive tumour size (p = 0.02), ER positivity (p = 0.007) and shorter tumour-to-skin distance (p = 0.05) correlated with nodal metastasis. HER2 was not included in multivariate analysis as there was no association with nodal status on univariate analysis. In node-positive tumours, as tumour size increased, the tumour-to-skin distance decreased (r = − 0.34, p = 0.026). In node-negative tumours, there was no correlation (r = + 0.18, p = 0.23). Conclusion: This study shows that non-locally advanced cancers closer to the skin (and consequent proximity to subdermal lymphatics) are associated with a greater risk of nodal metastasis. Pre-operative identification of those more likely to be node positive may suggest the need for a second-look USS since a higher nodal stage may lead to a change in therapeutic strategies, such as upfront systemic therapy, node marking, and axillary clearance without the need to return to theatre following sentinel node biopsy. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index